GKOS vs WST: stock comparison and AI forecast
Glaukos Corp (GKOS) and West Pharmaceutical Services Inc (WST) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GKOS Glaukos Corp
- Price
- $238.61 +75.6% · 6M
- Market Cap
- $14.07B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
WST West Pharmaceutical Services Inc
- Price
- $407.88 +35.9% · 6M
- Market Cap
- $28.70B
- P/E Ratio
- 45.8x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- WST is 2.0 times larger than GKOS by market capitalization ($28.70B against $14.07B).
- Over the last six months GKOS returned +75.6% and WST +35.9%.
- WST turns 18.8% of its revenue into net income, against -24.6% for GKOS.
- GKOS carries 0.37 times debt per unit of equity, against 0.37 times for WST.
- WST yields 0.22% in dividends; GKOS pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GKOS | WST |
|---|---|---|
| Market Cap | $14.07B | $28.70B |
| P/E Ratio | – | 45.78x |
| P/B Ratio | 19.62x | 9.67x |
| Dividend Yield | – | 0.22% |
| EPS | $-2.97 | $8.91 |
| Book Value/Share | $12.16 | $42.18 |
| Revenue/Share | $11.70 | $48.27 |
| FCF/Share | $0.61 | $6.44 |
Profitability & Margins
| Metric | GKOS | WST |
|---|---|---|
| ROE | -23.7% | 21.5% |
| ROA | -17.3% | 15.7% |
| ROIC | -20.7% | 22.8% |
| Gross Margin | 81.1% | 37.6% |
| Operating Margin | -25.5% | 23.0% |
| Net Margin | -24.6% | 18.8% |
| EBT Margin | -25.3% | 23.2% |
| Tax Rate | 2.7% | 21.3% |
Financial Health
| Metric | GKOS | WST |
|---|---|---|
| Current Ratio | 4.57x | 2.82x |
| Quick Ratio | 4.09x | 2.10x |
| D/E Ratio | 0.37x | 0.37x |
| Financial Leverage | 1.37x | 1.37x |
| Interest Coverage | 0.8x | 10.4x |
| Working Capital | $453M | $1.17B |
Cash Flow
| Metric | GKOS | WST |
|---|---|---|
| Operating Cash Flow | $48M | $654M |
| Free Cash Flow | $36M | $453M |
| Capital Spending | -$12M | -$201M |
| OCF Growth YoY | – | -5.7% |
| FCF Growth YoY | – | 19.6% |
| FCF/Sales | 5.2% | 13.3% |
| CapEx/Sales | 1.7% | 5.9% |
Operational Efficiency
| Metric | GKOS | WST |
|---|---|---|
| Asset Turnover | 0.70x | 0.84x |
| Receivables Turnover | 4.6x | 4.5x |
| Inventory Turnover | 2.1x | 4.6x |
| Fixed Assets Turnover | 6.2x | 2.0x |
| Days Sales Outstanding | 79 days | 80 days |
| Days Inventory | 171 days | 80 days |
| Payables Period | 68 days | 43 days |
| Cash Conversion Cycle | 182 days | 117 days |
Income Statement
| Metric | GKOS | WST |
|---|---|---|
| Total Revenue | $690M | $3.40B |
| Operating Income | -$176M | $780M |
| Net Income | -$170M | $639M |
| R&D Expense | $170M | $76M |
| SG&A Expense | $435M | $437M |
| Cost of Goods Sold | $130M | $2.12B |
Dividend & Shareholder Information
| Metric | GKOS | WST |
|---|---|---|
| Dividends Per Share | – | $0.89 |
| Payout Ratio | – | 10.0% |
| Shares Outstanding | 59M | 70M |
| Net Income Growth | – | 29.9% |
| EPS Growth | – | 32.0% |
GKOS vs WST: stock comparison and AI forecast
Which is bigger, GKOS or WST?
WST is 2.0 times larger than GKOS by market capitalization ($28.70B against $14.07B).
Which stock performed better over the last six months, GKOS or WST?
Over the last six months GKOS returned +75.6% and WST +35.9%.
Which one does Intratio's AI model rank higher, GKOS or WST?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.